Skip to main content
Clinical Trials/NCT03571776
NCT03571776TerminatedNot Applicable

Anti-mullerian Hormone in Ovarian Reserve Evaluation After Treatment of Endometriomas With Alcohol Sclerotherapy Versus Surgery: Clinical Trial

Hospital Universitari de Bellvitge2 sites in 1 country158 target enrollmentStarted: June 5, 2018Last updated:
Conditions

Trial Snapshot

Phase
Not Applicable
Status
Terminated
Sponsor
Enrollment
158
Locations
2
Primary Endpoint
Change from Baseline AMH Test

Study Overview

Brief Summary

The purpose of this multicenter study is to compare the ovarian reserve after alcohol sclerosis of the endometriomas against conventional surgery (AMH, follicle stimulating hormone (FSH) and antral follicles count) as well as the complications and costs between the 2 procedures.

Detailed Description

Clinical Trial Phase III, Multicenter, National, open, parallel-group assignment 1: 1, stratified by age, previous oophorectomy and uni- or bilateral ovarian involvement. Patients with suspected ovarian endometrioma by ultrasound will be randomized into 2 groups: (a) Study Group: echoguided aspiration plus sclerosis with alcohol; (B) Control group: Laparoscopic Cystectomy. Pre-treatment, and 6 months after treatment, AMH values will be determined. Complications, recurrences and costs from each treatment will be collected.

Study Design

Study Type
Interventional
Allocation
Randomized
Intervention Model
Parallel
Primary Purpose
Treatment
Masking
None

Eligibility Criteria

Ages
18 Years to 45 Years (Adult)
Sex
Female
Accepts Healthy Volunteers
No

Inclusion Criteria

  • Uni- or bilocular endometrioma according ultrasounds
  • Endometrioma size: 30-100 mm when symptoms were present and 50-100 mm if asymptomatics
  • > 3 months from diagnosis
  • Ca125 <200 IU/mL and human epididymis protein 4 (HE4) < 70,

Exclusion Criteria

  • Previous gynecological cancer
  • Symptomatic severe extraovarian endometriosis
  • Dermoid or high risk of malignancy cysts
  • Pregnancy
  • Mental disability

Outcomes

Primary Outcomes

Change from Baseline AMH Test

Time Frame: prior and 6 months after both procedures

the value of AMH in ng/mL

Secondary Outcomes

  • Costs(1 month after the procedure)
  • Change from Baseline antral follicles count(prior and 6 months after both procedures)
  • Complications(1 month after the procedure)
  • Change from Baseline Pain(prior and 6 months after both procedures)

Investigators

Sponsor
Hospital Universitari de Bellvitge
Sponsor Class
Other
Responsible Party
Principal Investigator
Principal Investigator

Amparo Garcia-Tejedor

Principal Investigator

Hospital Universitari de Bellvitge

Study Sites (2)

Loading locations...

Similar Trials